[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TR200002338T2 - Stratejik olarak yenilenmiş hepatit B çekirdek proteinler. - Google Patents

Stratejik olarak yenilenmiş hepatit B çekirdek proteinler.

Info

Publication number
TR200002338T2
TR200002338T2 TR2000/02338T TR200002338T TR200002338T2 TR 200002338 T2 TR200002338 T2 TR 200002338T2 TR 2000/02338 T TR2000/02338 T TR 2000/02338T TR 200002338 T TR200002338 T TR 200002338T TR 200002338 T2 TR200002338 T2 TR 200002338T2
Authority
TR
Turkey
Prior art keywords
hepatitis
strategically
regenerated
protein
modified
Prior art date
Application number
TR2000/02338T
Other languages
English (en)
Inventor
J. Birkett Ashley
Original Assignee
Immune Complex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Complex Corporation filed Critical Immune Complex Corporation
Publication of TR200002338T2 publication Critical patent/TR200002338T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/795—Composed of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/894—Manufacture, treatment, or detection of nanostructure having step or means utilizing biological growth
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Tecihen, nükleokapsid proteinin immünodominant yani bagisiklik saglama açisindan baskin olan, kimyasal olarak reaksiyona girebilen bir amino asit kalintisi içeren, bir bölgesinden yapilan bir eklemeyle, stratejik olarak degistirilmis bir hepatit B çekirdek proteini açiklanmaktadir. Degistirilmis hepatit B çekirdek proteini ya da toplu halde bulunan nüklepkapsid protein tanecikleri, degisime ugratilmis bir nükleokapsid bilesigi olusturmak için bir hapten ile birlesebilmektedir. Bu gibi bir bilesik asilarin ya da antikorlarin hazirlanmasinda kullanilabilmektedir. Degisime ugratilmis hepatit B çekirdek proteini bir T hücresi özünü içerecek sekilde de degisime ugratilabilmektedir.
TR2000/02338T 1998-02-12 1999-02-11 Stratejik olarak yenilenmiş hepatit B çekirdek proteinler. TR200002338T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7453798P 1998-02-12 1998-02-12

Publications (1)

Publication Number Publication Date
TR200002338T2 true TR200002338T2 (tr) 2002-06-21

Family

ID=22120092

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02338T TR200002338T2 (tr) 1998-02-12 1999-02-11 Stratejik olarak yenilenmiş hepatit B çekirdek proteinler.

Country Status (20)

Country Link
US (1) US6231864B1 (tr)
EP (1) EP1054689B1 (tr)
JP (1) JP4480268B2 (tr)
KR (1) KR100581991B1 (tr)
CN (1) CN100387622C (tr)
AT (1) ATE249240T1 (tr)
AU (1) AU767144B2 (tr)
BR (1) BR9907855A (tr)
CA (1) CA2320488C (tr)
CZ (1) CZ302092B6 (tr)
DE (1) DE69911175T2 (tr)
DK (1) DK1054689T3 (tr)
ES (1) ES2207177T3 (tr)
HK (1) HK1038306A1 (tr)
ID (1) ID26669A (tr)
IL (2) IL137766A0 (tr)
NZ (1) NZ506245A (tr)
PT (1) PT1054689E (tr)
TR (1) TR200002338T2 (tr)
WO (1) WO1999040934A1 (tr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP2010510960A (ja) 1998-11-30 2010-04-08 サイトス バイオテクノロジー アーゲー 抗原の順序付けられた分子提示、提示の方法、および使用
WO2000046365A1 (en) * 1999-02-02 2000-08-10 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
US6887464B1 (en) * 1999-02-02 2005-05-03 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
WO2001016174A2 (en) * 1999-08-30 2001-03-08 Rolf Kiessling Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopes of mycobacterial heat shock protein 65
KR20090085697A (ko) 2000-02-23 2009-08-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
WO2001085208A2 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US6942866B2 (en) * 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
NZ527664A (en) * 2001-02-05 2006-12-22 Stressgen Biotechnologies Corp Hepatitis B virus vaccine comprising a stress protein and an HBV antigen
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030037327A1 (en) * 2001-08-15 2003-02-20 International Business Machines Corporation Run-time rule-based topological installation suite
US20040146524A1 (en) * 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
JP4360906B2 (ja) * 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
DK1450856T3 (da) 2001-09-14 2010-05-31 Cytos Biotechnology Ag Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
BR0213117A (pt) 2001-10-05 2004-09-21 Cytos Biotechnology Ag Conjugados peptìdeo angiotensina-veìculo e seus usos
CA2476755C (en) 2001-12-17 2014-08-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
AU2003212985A1 (en) * 2002-02-08 2003-09-02 New York University Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies
AU2003213168A1 (en) * 2002-02-21 2003-12-19 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
AU2003213194A1 (en) * 2002-02-21 2003-09-09 Apovia, Inc. IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY
WO2003072731A2 (en) * 2002-02-21 2003-09-04 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
EP1513552B1 (en) * 2002-06-20 2010-12-01 Cytos Biotechnology AG Packaged virus-like particles in combination with cpg for use as adjuvants with allergens : method of preparation and use
EP2351770A1 (en) * 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
JP5084103B2 (ja) * 2002-07-18 2012-11-28 サイトス バイオテクノロジー アーゲー ハプテン担体抱合体およびその用法
RU2450827C2 (ru) * 2002-07-19 2012-05-20 Цитос Биотехнологи Аг Композиции вакцин, содержащие наборы антигенов в виде амилоида бета 1-6
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US7517520B2 (en) * 2003-03-26 2009-04-14 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US20070087331A1 (en) * 2003-05-15 2007-04-19 Cytos Biotechnology Ag Selection of b cells with specificity if interest: method of preparation and use
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
NO345763B1 (no) 2003-06-16 2021-07-19 Celltech R&D Inc Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering.
US7883843B2 (en) 2003-07-30 2011-02-08 Vaccine Research Institute Of San Diego Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US7320795B2 (en) 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
CN1305527C (zh) * 2003-11-21 2007-03-21 薛平 乙型肝炎治疗疫苗及其制备方法
US20050191317A1 (en) * 2004-01-20 2005-09-01 Cytos Biotechnology Ag Ghrelin-carrier conjugates
EP1766094A4 (en) 2004-05-18 2009-11-25 Vical Inc INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE
WO2006033679A2 (en) * 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
US20080199493A1 (en) 2004-05-25 2008-08-21 Picker Louis J Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
CA2648718A1 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
AU2007348315A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating B- cell malignancies
EP2134740A2 (en) * 2007-04-09 2009-12-23 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
WO2009029272A2 (en) * 2007-08-27 2009-03-05 Agadjanyan Michael G Epitope vaccine for prevention and reversion of ad pathology
WO2009099678A1 (en) 2008-02-09 2009-08-13 Sanofi Pasteur Biologics Co. Influenza b vaccines
CN101423555B (zh) * 2008-11-14 2011-04-20 四川大学华西医院 特异性阻断乙肝病毒组装和复制的膜穿透性多肽
MX337723B (es) 2008-12-09 2016-03-15 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige.
EP2391383B1 (en) 2009-02-02 2015-12-23 ChronTech Pharma AB Codon-optimized hepatitis b virus core antigen (hbcag)
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
CN102596236B (zh) * 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
PE20161551A1 (es) 2009-09-03 2017-01-18 Pfizer Vaccines Llc Vacuna de pcsk9
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
ES2643389T3 (es) 2011-02-12 2017-11-22 Globeimmune, Inc. Producto terapéutico basado en levadura para infección por hepatitis B crónica
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
EP2723365A1 (en) 2011-06-21 2014-04-30 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
PT2888284T (pt) * 2012-08-21 2022-11-18 Janssen Pharmaceutica Nv Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
WO2014116730A2 (en) 2013-01-23 2014-07-31 The Board Of Trustees Of The Leland Stanford Junior University Stabilized hepatitis b core polypeptide
JP2016517440A (ja) * 2013-03-15 2016-06-16 ブイエルピー バイオテック，インコーポレイテッド パリビズマブエピトープベースのウイルス様粒子
AU2014228784A1 (en) 2013-03-15 2015-10-08 Vlp Biotech, Inc. Rodent hepadnavirus cores with reduced carrier-specific antigenicity
GB201402890D0 (en) 2014-02-18 2014-04-02 Iqur Ltd Vaccines based on hepatitis B Core antigens
CN104208670B (zh) * 2014-09-09 2017-07-28 韩自勤 一种治疗乙肝的药物组合物
GB201505041D0 (en) * 2015-03-25 2015-05-06 Iqur Ltd Vaccines based on hepatitis B core antigens
CN107383176A (zh) * 2017-05-10 2017-11-24 于学杰 用于对汉滩病毒和汉城病毒引起的肾综合征出血热分型的多肽
WO2018237313A1 (en) * 2017-06-23 2018-12-27 American Type Culture Collection (Atcc) VIRAL PSEUDO PARTICLES COMPRISING A ZIKA ANTIGEN
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
CN110804097B (zh) * 2019-10-30 2021-02-26 云南沃森生物技术股份有限公司 一种同时制备两种单克隆抗体的方法
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
EP4412711A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
KR20230121575A (ko) 2022-02-10 2023-08-18 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB8903313D0 (en) * 1989-02-14 1989-04-05 Wellcome Found Conjugates
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US5840303A (en) * 1991-08-26 1998-11-24 The Scripps Research Foundation Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
AU4248297A (en) * 1996-09-03 1998-03-26 General Hospital Corporation, The Inhibition of viral replication

Also Published As

Publication number Publication date
AU2675399A (en) 1999-08-30
WO1999040934A1 (en) 1999-08-19
ID26669A (id) 2001-01-25
KR20010052165A (ko) 2001-06-25
DK1054689T3 (da) 2004-01-26
EP1054689A4 (en) 2002-02-13
CZ302092B6 (cs) 2010-10-06
IL137766A0 (en) 2001-10-31
IL137766A (en) 2007-12-03
JP2002509700A (ja) 2002-04-02
DE69911175T2 (de) 2004-07-29
CA2320488A1 (en) 1999-08-19
ATE249240T1 (de) 2003-09-15
NZ506245A (en) 2003-08-29
CZ20002819A3 (en) 2001-06-13
BR9907855A (pt) 2001-04-24
DE69911175D1 (de) 2003-10-16
US6231864B1 (en) 2001-05-15
CN100387622C (zh) 2008-05-14
EP1054689B1 (en) 2003-09-10
AU767144B2 (en) 2003-10-30
EP1054689A1 (en) 2000-11-29
CA2320488C (en) 2007-03-06
KR100581991B1 (ko) 2006-05-23
CN1300222A (zh) 2001-06-20
ES2207177T3 (es) 2004-05-16
PT1054689E (pt) 2003-11-28
JP4480268B2 (ja) 2010-06-16
HK1038306A1 (en) 2002-03-15

Similar Documents

Publication Publication Date Title
TR200002338T2 (tr) Stratejik olarak yenilenmiş hepatit B çekirdek proteinler.
DE60122286D1 (de) Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
ATE162402T1 (de) Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff
AU8223187A (en) T cell epitopes of the hepatitis b virus nucleocapsid protein
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
NO934542L (no) Hepatitt C virus (HCV) polypeptider
IE811595L (en) Synthetic peptide antigens
AU600466B2 (en) Htlv-iii envelope peptides
AR001731A1 (es) Nueva celulasa método para producirla composición que la contiene vector que comprende al adn que lacodifica celula huesped método de aplicación
ATE185350T1 (de) Synthetische antigene zum nachweis von antikörpern gegen hepatitis c virus
WO1993001210A3 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
FI854396A0 (fi) Syntetisk hepatitis b-virus vaccin som innehaoller baode t-cellens och b-cellens determinanter.
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
WO1995016040A3 (en) Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
EP1356076A4 (en) METHODS AND COMPOSITIONS FOR EXTRACTING PROTEINS FROM CELLS
OA09653A (en) Rubella peptides
KR860001882A (ko) 왁진 효능이 있는 폴리펩타이드
FI923020A0 (fi) Inte a inte b-sekvenser.
YU45292A (sh) Različiti površinski proteini hepatitis b virusa koji obrazuju čestice
IL106592A0 (en) Peptides,analogues and mixtures thereof for detecting and eliciting antibodies to the e1 and e2 protein of rubella virus
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты
Miller et al. 4.4 Long-term lines of channel catfish lymphocytes produce both enhancing and suppressing “factors”
KR970010787A (ko) B형 간염 바이러스 표면항원과 c형 간염 바이러스 외피 단백질의 융합 단백질 및 이를 포함하는 혼합 백신